


PHARMACEUTICAL 2023

VERTEX PHARMACEUTICALS INC MA Rank 48 of 446







PHARMACEUTICAL 2023

Rank 48 of 446



VERTEX PHARMACEUTICALS INC MA



The relative strengths and weaknesses of VERTEX PHARMACEUTICALS INC MA are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VERTEX PHARMACEUTICALS INC MA compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 104% points. The greatest weakness of VERTEX PHARMACEUTICALS INC MA is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 4.6% points.

The company's Economic Capital Ratio, given in the ranking table, is 243%, being 200% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	13,234,800
Cost of Goods Sold	1,080,300
Intangible Assets	1,691,600
Liabilities, Current	2,742,100
Liabilities, Non-Current	1,065,300
Other Assets	3,224,500
Other Compr. Net Income	-15,100
Other Expenses	968,400
Other Liabilities	430,800
Other Net Income	-75,000
Other Revenues	8,930,700
Property and Equipment	0
Research and Development	2,540,300
Selling, General and Administrative Expense	944,700

Output Variable	Value in 1000 USD
Assets	18,150,900
Liabilities	4,238,200
Expenses	5,533,700
Revenues	8,930,700
Stockholders Equity	13,912,700
Net Income	3,322,000
Comprehensive Net Income	3,314,450
Economic Capital Ratio	243%

